Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience

Systematic review with meta‐analysis: the efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose previous anti‐TNF treatment has failed

“…The literature search revealed 797 references in Pubmed and 1067 in Embase; however, some references were excluded, among other reasons, for duplication and non‐availability of data on the effectiveness of the second anti‐TNF . Finally, only 46 studies met the inclusion criteria and were included . Of these, 37 focused on CD (Tables S1 and S2), 8 on UC, and 1 on pouchitis (Table S3).…”

“…Studies were classified by type of IBD in order to pool data and perform the statistical meta‐analysis; therefore, the pouchitis study was excluded from the meta‐analysis. Of the CD studies, 32 evaluated switching from IFX to ADA, 4 switching from IFX to CZP, and 1 switching from ADA to IFX . All UC studies evaluated switching from IFX to ADA.…”

“…Severe and serious adverse events related to the administration of a second anti-TNF Forty-two of 46 studies reported the AE rates with the second anti-TNF therapy. Of those, in 15 studies it was not possible to separately extract the AEs that occurred with the second-line anti-TNF therapy (as AEs were provided jointly with those of patients na€ ıve to biological therapy), 3,18,25,26,30,33,37,47,49,53,54,56,59,62 so they were excluded from this analysis (Table S5). In CD, the incidence of AEs ranged from 0% to 81%, being the intensity of them relatively low, when it was specified.…”

Letter: glucocorticoids use and the risk of colorectal cancer

“…1,2 Although antibodies against tumour necrosis factor a (anti-TNFa) drugs induce and maintain remission in inflammatory bowel diseases, approximately 30% of patients do not respond to these medications, and up to 40% of responders need multiple dose adjustments to maintain remission in the long term. [3][4][5][6][7] Monitoring the treatment based on anti-TNFa and antibodies to the drug serum levels seems to be a promising tool to optimise therapy with these medications. However, several questions about this strategy remain unanswered.…”

Letter: dry blood spots for anti‐TNF treatment monitoring in IBD – authors’ reply

“…Although antibodies against tumour necrosis factor a (anti-TNFa) drugs induce and maintain remission in inflammatory bowel diseases, approximately 30% of patients do not respond to these medications, and up to 40% of responders need multiple dose adjustments to maintain remission in the long term. [3][4][5][6][7] Monitoring the treatment based on anti-TNFa and antibodies to the drug serum levels seems to be a promising tool to optimise therapy with these medications. However, several questions about this strategy remain unanswered.…”